Regeneron Pharmaceuticals Says Libtayo Achieves 37% Reduction In Risk Of Death At 44 Months (Hr 0.63)

Oct 25 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:

• REGENERON PHARMACEUTICALS - LIBTAYO ACHIEVES 37% REDUCTION IN RISK OF DEATH AT 44 MONTHS (HR: 0.63)

• REGENERON PHARMACEUTICALS - LIBTAYO CONFIRMS SUSTAINED DISEASE-FREE SURVIVAL BENEFIT INCLUDING MRD NEGATIVE PATIENTS

Further company coverage: REGN.O